Evidence map›Paper›PMID 28524540›Full record

ArticleJournal of cellular and molecular medicine2017

Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma.

Peter Kubatka, Sona Uramova, Martin Kello, Karol Kajo, Peter Kruzliak, Jan Mojzis, Desanka Vybohova, Marian Adamkov, Karina Jasek, Zora Lasabova and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Chemopreventive and therapeutic effects ofFrontiers in pharmacology · 2025
    Article
  6. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  7. Review
  8. Frontiers in pharmacology · 2024
    Article
  9. Article
  10. Frontiers in oncology · 2024
    Article
  11. Review
  12. Review
  13. Antibiotics (Basel, Switzerland) · 2022
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. International journal of molecular sciences · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 4 countries.

Peter KubatkaDepartment of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.ORCID http://orcid.org/0000-0003-4312-5076
Sona UramovaDepartment of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Martin KelloDepartment of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia.
Karol KajoDepartment of Pathology, Slovak Medical University and St. Elisabeth Oncology Institute, Bratislava, Slovakia.
Peter KruzliakDepartment of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
Jan MojzisDepartment of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia.
Desanka VybohovaDepartment of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Marian AdamkovDepartment of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Karina JasekDivision of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Zora LasabovaDivision of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Pavol ZuborDepartment of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Silvia FialovaDepartment of Pharmacognosy and Botany, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
Svetlana DokupilovaDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Toxicological and Antidoping Center, Comenius University in Bratislava, Bratislava, Slovakia.
Peter SolarInstitute of Biology and Ecology, Faculty of Science, Laboratory of Cell Biology, P. J. Safarik University, Kosice, Slovakia.
Martin PecDepartment of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Katarina AdamicovaDepartment of Pathological Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Jan DankoDepartment of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Mariusz AdamekDepartment of Thoracic Surgery, Faculty of Medicine and Dentistry, Medical University of Silesia, Katowice, Poland.
Dietrich BusselbergQatar Foundation-Education City, Weill Cornell Medicine in Qatar, Doha, Qatar.
Comenius University Bratislava · SKUniversity of Pavol Jozef Šafárik · SKMedical University of Silesia · PLSlovak Medical University · SKUniversity of Veterinary Sciences Brno · CZWeill Cornell Medical College in Qatar · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is supposed that plant functional foods, rich in phytochemicals, may potentially have preventive effects in carcinogenesis. In this study, the anticancer effects of cloves in the in vivo and in vitro mammary carcinoma model were assessed. Dried flower buds of cloves (CLOs) were used at two concentrations of 0.1% and 1% through diet during 13 weeks after the application of chemocarcinogen. After autopsy, histopathological and immunohistochemical analyses of rat mammary carcinomas were performed. Moreover, in vitro evaluation using MCF-7 cells was carried out. Dietary administered CLO caused the dose-dependent decrease in tumour frequency by 47.5% and 58.5% when compared to control. Analysis of carcinoma cells in animals showed bcl-2, Ki67, VEGFA, CD24 and CD44 expression decrease and Bax, caspase-3 and ALDH1 expression increase after high-dose CLO administration. MDA levels were substantially decreased in rat carcinomas in both CLO groups. The evaluation of histone modifications revealed increase in lysine trimethylations and acetylations (H4K20me3, H4K16ac) in carcinomas after CLO administration. TIMP3 promoter methylation levels of CpG3, CpG4, CpG5 islands were altered in treated cancer cells. An increase in total RASSF1A promoter methylation (three CpG sites) in CLO 1 group was found. In vitro studies showed antiproliferative and pro-apoptotic effects of CLO extract in MCF-7 cells (analyses of cytotoxicity, Brdu, cell cycle, annexin V/PI, caspase-7, Bcl-2 and mitochondrial membrane potential). This study showed a significant anticancer effect of clove buds in the mammary carcinoma model in vivo and in vitro.

Indexed as

AdenocarcinomaAldehyde Dehydrogenase 1 FamilyAnimalsAntineoplastic Agents, Phytogenicbcl-2-Associated X ProteinBreast NeoplasmsCaspase 3DNA MethylationDose-Response Relationship, DrugEpigenesis, GeneticFemaleFlowersHistonesHumansKi-67 AntigenMammary Neoplasms, ExperimentalAldehyde Dehydrogenase 1 FamilyAldh1a1 protein, ratAntineoplastic Agents, PhytogenicBax protein, ratbcl-2-Associated X ProteinBcl2 protein, ratCasp3 protein, ratCaspase 3HistonesKi-67 AntigenPlant ExtractsProto-Oncogene Proteins c-bcl-2RASSF1 protein, ratRetinal DehydrogenaseTumor Suppressor ProteinsVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratangiogenesisapoptosiscancer stem cellscell proliferationclovesepigeneticsmammary carcinogenesisMCF-7 cellsrat

Identifiers

PMID28524540
PMCPMC5661249
OpenAlexW2615859300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.